Patient characteristics and outcomes by aPL status at follow-up
| . | APS (n = 11) . | Transient or low-titer aPL (n = 70) . | P value . |
|---|---|---|---|
| Median age (IQR), y | 15.8 (13.4-17.8) | 9.9 (2-15.9) | .014 |
| Sex female, n (%) | 7 (64) | 30 (43) | .329 |
| Index VTE anatomical site, n (%) | 1.00 | ||
| Upper or lower extremity | 8 (73) | 48 (69) | |
| Cerebral sinus venous thrombosis | 2 (18) | 11 (16) | |
| Other (splanchnic vein, IVC, or IJ only) | 1 (9) | 11 (16) | |
| Length of anticoagulation therapy, n (%) | - | ||
| 6-wk therapy | - | 25 (36) | |
| 3-mo therapy | 11 (100) | 45 (64) | |
| Complete veno-occlusion at 6 wk after VTE | 1 (9) | 7 (10) | 1.00 |
| VTE-provoking factor, n (%) | |||
| Catheter-associated VTE, n (%) | 3 (27) | 30 (43) | .511 |
| Infection | 4 (36) | 26 (37) | .764 |
| Autoimmune/inflammatory disease | 0 | 3 (4) | .72 |
| Trauma or surgery | 3 (27) | 9 (13) | .164 |
| Other (dehydration and genetic syndrome) | 1 (9) | 8 (11) | .686 |
| Type of aPL at enrollment, no. of positive (%) | |||
| LAS-aPTT | 3 (27) | 7 (10) | .325 |
| Dilute Russell’s viper venom time | 5 (45) | 31 (44) | .567 |
| STACLOT LA | 3 (27) | 23 (33) | .505 |
| Anti-cardiolipin IgM | 1 (9) | 12 (17) | .681 |
| aβ2GP IgG/IgM | 3 (27) | 10 (14) | .377 |
| High titer aPL at enrollment (>40 MPL, SGU, or SMU U/mL), n (%) | |||
| Anti-cardiolipin IgM | 0 | 0 | - |
| aβ2GP IgG | 1 (9) | 1 (1) | .274 |
| aβ2GP IgM | 1 (9) | 1 (1) | .274 |
| Outcomes (1 y after VTE) | |||
| Symptomatic recurrent VTE | 2 (18) | 1 (1) | .047 |
| Anticoagulant-associated CRB | 1 (9) | 0 | .135 |
| . | APS (n = 11) . | Transient or low-titer aPL (n = 70) . | P value . |
|---|---|---|---|
| Median age (IQR), y | 15.8 (13.4-17.8) | 9.9 (2-15.9) | .014 |
| Sex female, n (%) | 7 (64) | 30 (43) | .329 |
| Index VTE anatomical site, n (%) | 1.00 | ||
| Upper or lower extremity | 8 (73) | 48 (69) | |
| Cerebral sinus venous thrombosis | 2 (18) | 11 (16) | |
| Other (splanchnic vein, IVC, or IJ only) | 1 (9) | 11 (16) | |
| Length of anticoagulation therapy, n (%) | - | ||
| 6-wk therapy | - | 25 (36) | |
| 3-mo therapy | 11 (100) | 45 (64) | |
| Complete veno-occlusion at 6 wk after VTE | 1 (9) | 7 (10) | 1.00 |
| VTE-provoking factor, n (%) | |||
| Catheter-associated VTE, n (%) | 3 (27) | 30 (43) | .511 |
| Infection | 4 (36) | 26 (37) | .764 |
| Autoimmune/inflammatory disease | 0 | 3 (4) | .72 |
| Trauma or surgery | 3 (27) | 9 (13) | .164 |
| Other (dehydration and genetic syndrome) | 1 (9) | 8 (11) | .686 |
| Type of aPL at enrollment, no. of positive (%) | |||
| LAS-aPTT | 3 (27) | 7 (10) | .325 |
| Dilute Russell’s viper venom time | 5 (45) | 31 (44) | .567 |
| STACLOT LA | 3 (27) | 23 (33) | .505 |
| Anti-cardiolipin IgM | 1 (9) | 12 (17) | .681 |
| aβ2GP IgG/IgM | 3 (27) | 10 (14) | .377 |
| High titer aPL at enrollment (>40 MPL, SGU, or SMU U/mL), n (%) | |||
| Anti-cardiolipin IgM | 0 | 0 | - |
| aβ2GP IgG | 1 (9) | 1 (1) | .274 |
| aβ2GP IgM | 1 (9) | 1 (1) | .274 |
| Outcomes (1 y after VTE) | |||
| Symptomatic recurrent VTE | 2 (18) | 1 (1) | .047 |
| Anticoagulant-associated CRB | 1 (9) | 0 | .135 |
MPL, microgram of IgM antibody; SGU, standard IgG anti-beta 2 glycoprotein unit; SMU, standard IgM anti-beta 2 glycoprotein unit.